Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Incyte Corporation
Novartis
Enliven Therapeutics
Novartis
Shenzhen TargetRx Co., Ltd.
Takeda
Novartis
Terns, Inc.
Novartis
Novartis
Novartis
Enliven Therapeutics
Ascentage Pharma Group Inc.